Completed PHASE3 INTERVENTIONAL NCT00719498

Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)

Early High-dose Erythropoietin Therapy and Hypothermia After Out-of-hospital Cardiac Arrest: A Matched Control Study

Sponsor: Janssen Cilag S.A.S.

Conditions Cardiac Arrest Cardiopulmonary Resuscitation

Interventions Epo-alpha

Updated 5 times since 2017 Last updated: May 16, 2011 Started: Nov 30, 2003 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00719498, this PHASE3 trial focuses on Cardiac Arrest and Cardiopulmonary and remains completed. Sponsored by Janssen Cilag S.A.S., it has been updated 5 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Cilag S.A.S.

Data source: Janssen Cilag S.A.S.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.